TX-LTTS
21.4.2022 15:33:06 CEST | Business Wire | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a global leading pure-play engineering services company, has garnered a multi-year $100 million+ electric air mobility deal from Jaunt Air Mobility (Jaunt). As part of the contract, LTTS will open an Engineering and R&D Centre in Québec Province for the next-gen electric aircraft manufacturer to provide engineering services for the Jaunt Journey eVTOL (electric Vertical Takeoff and Landing) air taxi.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220421005630/en/
Under the purview of Jaunt's Urban Air Mobility (UAM) business focus, LTTS will offer global engineering services to support and build the Jaunt Journey. Collectively these will encompass technology areas such as power distribution system, air data management, cockpit display system, flight control system, battery management, electrification, power electronics, structural design, stress analysis, testing, certification, and manufacturing engineering.
Jaunt is rolling out a new generation of sustainable aircraft to meet the growing demand for faster urban and regional travel. The Jaunt Journey takes off like a helicopter and transitions to flying like a fixed-wing plane using patented Slowed-Rotor Compound technology. These new air taxis will make it possible to travel more than 110 km in the air in 25 minutes or less, with trip costs affordable to the public. The Jaunt Journey, single-pilot aircraft, will carry four passengers. The vehicle will offer urban air mobility, cargo delivery, military missions, and medical transport.
Martin Peryea, CEO & CTO, Jaunt, said , "At Jaunt, our vision is to usher in a range of new-age aircraft-driven urban commuting that is fast, safe, and convenient. This new clean, sustainable aircraft will reduce carbon emissions worldwide. Strategically, we are continuing to grow our Tier 1 partnerships and recognize LTTS as a best-fit engineering partner, and together we are confident of pushing the mass-scale commercialization."
Eric Côté, President, Jaunt Air Mobility Canada, said , "The proposed Green Aerospace strategy created by federal and provincial governments makes it a perfect match for LTTS and Jaunt to offer end-to-end engineering support in structural design analysis and certification to develop the Jaunt Journey all-electric VTOL aircraft. LTTS has a history of working in Canada and can appreciate the potential behind this favorable environment."
Amit Chadha, Chief Executive Officer & Managing Director, L&T Technology Services, commented , "This deal is a milestone for team LTTS in view of the tremendous opportunities opening up in UAM and drone services which are emerging as alternatives to the increasingly congested on-ground mobility in cities. LTTS has a track record of developing high-performance engineering solutions for global Aerospace and Defense for over a decade and has supported critical defense programs in the past. We believe this program will set the benchmark for future UAM projects and our team is excited to build on this important engagement with Jaunt, with the eventual aim to make urban commuting safer, greener, efficient and reliable."
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 20,800 employees spread across 17 global design centers, 28 global sales offices and 89 innovation labs as of March 31, 2022. For more information, please visit https://www.ltts.com
About Jaunt Air Mobility LLC
Jaunt Air Mobility LLC is a transformative aerospace company headquartered in Dallas, Texas, in the US, with design and manufacturing in Montreal, Canada. Jaunt is building the best in the next generation of eVTOL (electric Vertical Takeoff and Landing) and hybrid-electric VTOL aircraft for faster travel over urban areas, moving people and packages. Jaunt is the global leader in Slowed-Rotor Compound (SRC) technology. The Jaunt Journey is the world's first aircraft combining helicopter and airplane flight capabilities. Together with Tier 1 aviation partners to develop the Journey, Jaunt intends to work with operators globally to provide this new form of travel. Jaunt offers the safest, quietest, most comfortable, and operationally efficient aircraft with a zero-carbon footprint. For more information, visit www.jauntairmobility.com .
On March 10, 2022, Jaunt became a wholly owned subsidiary of AIRO Group Holdings, Inc. (The AIRO Group). The AIRO Group will bring together decades of industry-leading technology with its group companies to provide best-in-class products and services uniquely capable of addressing a wide spectrum of aerospace markets. The AIRO Group leverages technologies that span data systems, resupply package delivery, military aerospace training, military, and commercial manned/unmanned aircraft systems, and avionics technologies. The company can be found at https://theairogroup.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005630/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom